These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15169642)

  • 1. Cure of experimental botulism and antibotulismic effect of toosendanin.
    Shi YL; Wang ZF
    Acta Pharmacol Sin; 2004 Jun; 25(6):839-48. PubMed ID: 15169642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toosendanin interferes with pore formation of botulinum toxin type A in PC12 cell membrane.
    Li MF; Shi YL
    Acta Pharmacol Sin; 2006 Jan; 27(1):66-70. PubMed ID: 16364212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological effects of toosendanin, an active ingredient of herbal vermifuge in Chinese traditional medicine].
    Shi YL; Wang WP
    Sheng Li Xue Bao; 2006 Oct; 58(5):397-406. PubMed ID: 17041722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine.
    Shi YL; Li MF
    Prog Neurobiol; 2007 May; 82(1):1-10. PubMed ID: 17363132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanisms of action of botulinum toxins and neurotoxins].
    Poulain B; Lonchamp E; Jover E; Popoff MR; Molgó J
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S73-6. PubMed ID: 19576489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toosendanin: synthesis of the AB-ring and investigations of its anti-botulinum properties (Part II).
    Nakai Y; Pellett S; Tepp WH; Johnson EA; Janda KD
    Bioorg Med Chem; 2010 Feb; 18(3):1280-7. PubMed ID: 20044261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The action of batulinum toxin at the neuromuscular junction.
    Sellin LC
    Med Biol; 1981 Feb; 59(1):11-20. PubMed ID: 6115105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication.
    Dickerson TJ; Janda KD
    ACS Chem Biol; 2006 Jul; 1(6):359-69. PubMed ID: 17163773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.
    Dembek ZF; Smith LA; Rusnak JM
    Disaster Med Public Health Prep; 2007 Nov; 1(2):122-34. PubMed ID: 18388640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.
    Atassi MZ; Oshima M
    Crit Rev Immunol; 1999; 19(3):219-60. PubMed ID: 10422600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms.
    Bradford AB; Machamer JB; Russo TM; McNutt PM
    Toxicol Appl Pharmacol; 2018 Feb; 341():77-86. PubMed ID: 29366638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptomatic treatment of botulism with a clinically approved small molecule.
    Vazquez-Cintron E; Machamer J; Ondeck C; Pagarigan K; Winner B; Bodner P; Kelly K; Pennington MR; McNutt P
    JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31996484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The binding sites of 3H-toosendanin in rat cerebral cortex homogenate].
    Shen GG; Zhuo XL; Shi YL
    Sheng Li Xue Bao; 1994 Dec; 46(6):546-52. PubMed ID: 7878482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Function-oriented synthesis applied to the anti-botulinum natural product toosendanin.
    Nakai Y; Tepp WH; Dickerson TJ; Johnson EA; Janda KD
    Bioorg Med Chem; 2009 Feb; 17(3):1152-7. PubMed ID: 19131252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in searching for therapeutics against Botulinum Neurotoxins.
    Pirazzini M; Rossetto O
    Expert Opin Drug Discov; 2017 May; 12(5):497-510. PubMed ID: 28271909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bimodal modulation of the botulinum neurotoxin protein-conducting channel.
    Fischer A; Nakai Y; Eubanks LM; Clancy CM; Tepp WH; Pellett S; Dickerson TJ; Johnson EA; Janda KD; Montal M
    Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1330-5. PubMed ID: 19164566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin.
    Zhou JY; Wang ZF; Ren XM; Tang MZ; Shi YL
    FEBS Lett; 2003 Dec; 555(2):375-9. PubMed ID: 14644446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human type A botulism and treatment with 3,4-diaminopyridine.
    Davis LE; Johnson JK; Bicknell JM; Levy H; McEvoy KM
    Electromyogr Clin Neurophysiol; 1992; 32(7-8):379-83. PubMed ID: 1526219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to design inhibitors of Clostridium botulinum neurotoxins.
    Cai S; Singh BR
    Infect Disord Drug Targets; 2007 Mar; 7(1):47-57. PubMed ID: 17346211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-botulism triterpenoid toosendanin elicits calcium increase and exocytosis in rat sensory neurons.
    Fang XF; Cui ZJ
    Cell Mol Neurobiol; 2011 Nov; 31(8):1151-62. PubMed ID: 21656151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.